ASMD (= Acid Sphingomyelinase Deficiency, Niemann-Pick Disease Type A/B) is based on the deficiency of the enzyme acid sphingomyelinase, which is caused by a defect in the SMPD1 gene. The lack of acid sphingomelinase leads to an accumulation of sphingomyelin in the cells of various organs (e.g. spleen and liver). Three clinical phenotypes are distinguished: infantile neurovisceral ASMD (Niemann-Pick disease type A), chronic neurovisceral ASMD (Niemann-Pick disease type A/B) and chronic visceral ASMD (Niemann-Pick disease type B). Infantile neurovisceral ASMD is characterized by hepatosplenomegaly, failure to thrive, psychomotor developmental retardation and progressive neurodegeneration. Life expectancy is significantly limited. Clinical signs of chronic neurovisceral ASMD include hepatosplenomegaly, interstitial lung disease and variable neurological symptoms (including ataxia, peripheral neuropathy, cognitive impairment). Visceral symptoms, such as hepatosplenomegaly and interstitial lung disease, are typical for chronic visceral ASMD. Enzyme replacement therapy with recombinant acid sphingomyelinase is currently in clinical trials.
Synonym: Niemann-Pick Disease Type A/B
Etiology: Deficiency of acid sphingomyelinase
Gene: SMPD1 Gene
Mode of inheritance: Autosomal recessive
Phenotypes:
Leading symptoms:
Infantile neuroviszerale ASMD
(Age of onset: infancy)
Chronic neuroviscerale ASMD
(Age of onset: childhood)
Chronic viscerale ASMD
(Age of onset: childhood, adolescence)
Diagnostics:
Therapy:
Only symptomatic
No age limit
Status inactive
Patient admission closed
Institution SphinCS GmbH
No age limit
Status active
Patient admission recruiting
Institution SphinCS Lyso gemeinnützige UG (haftungsbeschränkt)
Niemann-Pick Selbsthilfegruppe Deutschland e.V.
https://www.niemann-pick.de/
At the moment we are not aware of any self-help groups.
At present we have no literature available.